Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00403845
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG:
Indacaterol 150 μg
DRUG:
Indacaterol 300 μg
DRUG:
Placebo
Sponsor
Novartis